To determine if the novel regimen of PT/FLU+CY promotes cord blood engraftment in children's leukemia HSCT cohort
PTCy is a well-established haploidentical transplant regimen strategy. Moreover, unrelated cord blood (UCB) plays a critical role in the effects of GVL. However, the engraftment of grafts is unpredictable in the setting of a haplo-cord subsequent transplant. Therefore, applying a novel post-transplant regimen of PT/CY+FLU may selectively promote UCB engraftment in the setting of haplo-cord transplant.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
Nanfang Hospital
Guangzhou, Guangdong, China
RECRUITINGrate of UCB engraftment
evaluate the regimen if it promotes UCB engraftment
Time frame: initiate STR detection from day+15 thereafter weekly up to 1 year post-HSCT
rate of leukemia free survival
determine the leukemia status post-HSCT
Time frame: 3 years post-HSCT
rate of overall survival
determine the overall survival status post-HSCT
Time frame: 3 years post-HSCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.